anti-CD20-CAR-transduced T cells

Anti-CD20-CAR-transduced T cells are genetically engineered autologous or allogeneic human T lymphocytes that express a chimeric antigen receptor (CAR) specific for the B-cell surface protein CD20. The CAR construct typically consists of an extracellular single-chain variable fragment (scFv) derived from an anti-CD20 monoclonal antibody (such as Leu16), fused to intracellular signaling domains like 4-1BB and CD3ζ. These modified T cells recognize and kill malignant or pathogenic B-cells expressing CD20 through direct cytotoxicity and cytokine release. Anti-CD20-CAR-transduced T cell therapy is being developed primarily for the treatment of relapsed or refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as being explored in solid tumors like melanoma where a subset of tumor stem-like cells express CD20[2][4][5][6]. The product can be manufactured using lentiviral transduction methods in either autologous or allogeneic settings.

Other names

anti-CD20 chimeric antigen receptor T cellsanti-CD-20 chimeric antigen receptor T cellsanti-CD 20 chimeric antigen receptor T cellsCD20 CAR-T cellsCD-20 CAR-T cellsCD 20 CAR-T cellsanti-CD20 CAR+ Vδ1 γδ T cells